Literature DB >> 21881119

Stem cell therapy extends incubation and survival time in prion-infected mice in a time window-dependant manner.

Aroa Relaño-Ginés1, Sylvain Lehmann, Anna Bencsik, María Eugenia Herva, Juan Maria Torres, Carole A Crozet.   

Abstract

Prion diseases, which are mostly represented in humans by Creutzfeldt-Jakob disease, are transmissible neurodegenerative disorders characterized by vacuolization and neuronal loss, as well as by the accumulation of an abnormal form of the prion protein. These disorders have yet no effective treatment, and drugs that block prion replication in vitro do not significantly slow down the progression of the disease when used in vivo at late stages. Cell therapy that has been already tested in other neurodegenerative disorders therefore represents an interesting alternative approach. In this study, we showed for the first time in prion diseases that intracerebral transplantation of fetal neural stem cells significantly extended both incubation and survival time. This result was dependant on the time window chosen for the engraftment and was obtained with both genetically modified and wild-type stem cells, therefore forging a path toward efficient stem cell therapy for human prion diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21881119     DOI: 10.1093/infdis/jir484

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

1.  Prion diseases and adult neurogenesis: how do prions counteract the brain's endogenous repair machinery?

Authors:  Aroa Relaño-Ginés; Sylvain Lehmann; Carole Crozet
Journal:  Prion       Date:  2014-05-15       Impact factor: 3.931

Review 2.  Laboratory activities involving transmissible spongiform encephalopathy causing agents: risk assessment and biosafety recommendations in Belgium.

Authors:  Amaya Leunda; Bernadette Van Vaerenbergh; Aline Baldo; Stefan Roels; Philippe Herman
Journal:  Prion       Date:  2013-09-20       Impact factor: 3.931

3.  Comparison of the anti-prion mechanism of four different anti-prion compounds, anti-PrP monoclonal antibody 44B1, pentosan polysulfate, chlorpromazine, and U18666A, in prion-infected mouse neuroblastoma cells.

Authors:  Takeshi Yamasaki; Akio Suzuki; Rie Hasebe; Motohiro Horiuchi
Journal:  PLoS One       Date:  2014-09-02       Impact factor: 3.240

4.  Anti-Prion Screening for Acridine, Dextran, and Tannic Acid using Real Time-Quaking Induced Conversion: A Comparison with PrPSc-Infected Cell Screening.

Authors:  Jae Wook Hyeon; Su Yeon Kim; Sol Moe Lee; Jeongmin Lee; Seong Soo A An; Myung Koo Lee; Yeong Seon Lee
Journal:  PLoS One       Date:  2017-01-17       Impact factor: 3.240

5.  Prion replication occurs in endogenous adult neural stem cells and alters their neuronal fate: involvement of endogenous neural stem cells in prion diseases.

Authors:  Aroa Relaño-Ginès; Audrey Gabelle; Claire Hamela; Maxime Belondrade; Danielle Casanova; Chantal Mourton-Gilles; Sylvain Lehmann; Carole Crozet
Journal:  PLoS Pathog       Date:  2013-08-01       Impact factor: 6.823

6.  Systemic delivery of siRNA down regulates brain prion protein and ameliorates neuropathology in prion disorder.

Authors:  Sylvain Lehmann; Aroa Relano-Gines; Sarah Resina; Elsa Brillaud; Danielle Casanova; Charles Vincent; Claire Hamela; Sophie Poupeau; Mathieu Laffont; Audrey Gabelle; Constance Delaby; Maxime Belondrade; Jacques-Damien Arnaud; Maria-Teresa Alvarez; Jean-Claude Maurel; Patrick Maurel; Carole Crozet
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.